Multicentre protocol to individualize prostate biopsy in men with PI-RADS ≥3 lesions

A prospective 6-centre Chinese trial (n=300) will determine the optimal biopsy strategy for PI-RADS ≥3 lesions, using clinically significant prostate cancer detection as primary endpoint. PI-RADS 3 patients choose surveillance or systematic biopsy; PI-RADS ≥4 undergo combined ta…

• Primary outcome is the detection rate of clinically significant prostate cancer (International Society of Urological Pathology grade group ≥2).
• Secondary outcomes include any-cancer detection, false-negative rates, and complications.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.